Review of Current Dengue Treatment and Therapeutics in Development
- *Corresponding Author:
- Dahlene Fusco, MD, PhD
Department of Medicine
Massachusetts General Hospital
Boston, MA 02114
Received Date: May 02, 2014; Accepted Date: May 29, 2014; Published Date: May 31, 2014
Citation: Fusco DN, Chung RT (2014) Review of Current Dengue Treatment and Therapeutics in Development. J Bioanal Biomed S8: 002. doi: 10.4172/1948-593X.S8-002
Copyright: 2014 Fusco DN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Dengue is an arthropod-borne flavivirus associated with hemorrhagic fever and hemorrhagic shock. Roughly one third of the world population lives at risk of dengue infection, and it is not possible to accurately predict which patients are at risk for severe or fatal infection. Currently, there is no treatment for dengue infection. However, several classes of agents are in under investigation as potential anti-dengue drugs, including direct antivirals, host modula - tors, and RNAi therapeutics. These anti-dengue drugs in development will be reviewed here.